The SITC breaks its own embargo, and the ensuing chaos sees Replimune, Iovance and Incyte move.
Like many biotechs the group pushed on into phase III after a phase II failure; remarkably, the strategy has worked.
As investors continue to jump on small sparks of hope in the pandemic pipeline Sanofi and Regeneron inject a dose of reality.